— Vertex Pharmaceuticals (NASDAQ: VRTX) reported third-quarter 2019 earnings of $1.23 per share, vs. $1.15 per share expected
— Total revenue grew 21% to $949.8 million, vs $950.9 million expected.
— Reiterated FY19 product revenues guidance of $3.70 – 3.75 billion. Non-GAAP effective tax rate outlook was also unchanged at 21-22%.
— VRTX shares were down 0.14% immediately following the announcement.
Most Popular
COVID-19 drove retailers up the digital path years ahead than anticipated
Earlier we looked into how, during the COVID-19 pandemic, retailers saw changing trends in terms of their assortments and how the acceleration of online shopping led many of them to
Snowflake (SNOW) creates a record as the most successful software IPO ever; stock more than doubles
Data is at the heart of business innovation. Recognizing this trend, companies are seeking ways to transform their businesses by capturing, analyzing, and mobilizing data. The public cloud is becoming
Adobe (ADBE) sees new tailwinds as virtual shift gathers steam
The second half has been highly rewarding for design software maker Adobe Inc. (NASDAQ: ADBE) amid stable demand for digital content solutions. The company has remained unaffected by the virus-related